L. Almond

发表

Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model

M. Jamei, A. Rostami-Hodjegan, K. Rowland-Yeo, 2016, Drug Metabolism and Disposition.

Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs

B. Small, M. Jamei, K. Romero, 2021, CPT: pharmacometrics & systems pharmacology.

Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling

K. Rowland Yeo, L. Almond, H. Jones, 2020, Clinical pharmacology and therapeutics.

Development of a Multicompartment Permeability-Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs

M Jamei, L Almond, M. Jamei, 2015, CPT: pharmacometrics & systems pharmacology.

Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing.

Harvey J. Clewell, Barbara A. Wetmore, John F. Wambaugh, 2014, Toxicological sciences : an official journal of the Society of Toxicology.

Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model

Y. Daali, S. Rudaz, J. Desmeules, 2014, CPT: pharmacometrics & systems pharmacology.

Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro–In Vivo Extrapolation Model

C. Marzolini, C. Csajka, A. Owen, 2012, Clinical pharmacology and therapeutics.

An in vitro toolbox to accelerate anti-malarial drug discovery and development

David M. Shackleford, Dennis A. Smith, S. Charman, 2020, Malaria Journal.

Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals.

S. Khoo, D. Back, L. Almond, 2005, The Journal of antimicrobial chemotherapy.

The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro.

S. Khoo, A. Owen, J. Ford, 2003, Journal of acquired immune deficiency syndromes.

Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus‐infected individuals

S. Khoo, D. Back, L. Almond, 2005, Clinical pharmacology and therapeutics.

PBPK-led guidance for the treatment of cystic fibrosis patients taking elexacaftor-tezacaftor-ivacaftor with the newly approved fixed dose combination nirmatrelvir-ritonavir (PAXLOVID) for the treatment of COVID-19

L. Almond, A. Rao, B. Paul, 2022, medRxiv.

PBPK-led guidance for cystic fibrosis patients taking elexacaftor-tezacaftor-ivacaftor with nirmatrelvir-ritonavir for the treatment of COVID-19.

L. Almond, P. Beringer, A. Rao, 2022, Clinical pharmacology and therapeutics.

Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions.

K Rowland-Yeo, M Jamei, L Almond, 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

The relationship between nevirapine plasma concentrations and abnormal liver function tests.

S. Khoo, G. di Perri, M. Boffito, 2004, AIDS research and human retroviruses.

Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea

S. Khoo, R. Wood, D. Back, 2002, AIDS.

Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach

Marco Siccardi, Andrew Owen, David Back, 2013, Clinical Pharmacokinetics.

Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction.

M Jamei, M. Jamei, G. Tucker, 2009, Current drug metabolism.

Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

A Ke, Z Barter, K Rowland‐Yeo, 2016, CPT: pharmacometrics & systems pharmacology.

Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese Patients

M. Jamei, A. Rostami-Hodjegan, T. Johnson, 2011, Clinical pharmacokinetics.

Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach.

A. Owen, N. Liptrott, M. Siccardi, 2018, Drug metabolism and pharmacokinetics.

Physiologically Based Pharmacokinetic Modeling To Guide Management of Drug Interactions between Elexacaftor-Tezacaftor-Ivacaftor and Antibiotics for the Treatment of Nontuberculous Mycobacteria

L. Almond, P. Beringer, P. S. Chung, 2022, Antimicrobial agents and chemotherapy.

Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19

L. Almond, P. Beringer, A. Rao, 2022, Clinical Pharmacology and Therapeutics.

Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates

A. Owen, N. Liptrott, M. Siccardi, 2017, Pharmacology research & perspectives.

A Physiologically Based Pharmacokinetic Modeling Approach to Predict Disease–Drug Interactions: Suppression of CYP3A by IL‐6

M. Jamei, A. Rostami-Hodjegan, S. Wong, 2013, Clinical pharmacology and therapeutics.

Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: Mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series

L. Almond, P. Beringer, Joshua Wang, 2023, Pharmacotherapy.

Development and application of a PBPK modeling strategy to support antimalarial drug development

S. Charman, E. Howgate, K. Rowland-Yeo, 2023, CPT: pharmacometrics & systems pharmacology.